CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CRL - US1598641074 - Common Stock
219.52 USD
+1.33 (+0.61%)
Taking everything into account, CRL scores 4 out of 10 in our fundamental rating. CRL was compared to 57 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CRL was profitable.
- In the past year CRL had a positive cash flow from operations.
- In the past 5 years CRL has always been profitable.
- Each year in the past 5 years CRL had a positive operating cash flow.
1.2 Ratios
- CRL has a Return On Assets (-1.11%) which is comparable to the rest of the industry.
- The Return On Equity of CRL (-2.45%) is comparable to the rest of the industry.
- CRL has a better Return On Invested Capital (5.84%) than 73.68% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROIC | 5.84% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
- In the last couple of years the Profit Margin of CRL has declined.
- CRL has a better Operating Margin (11.73%) than 71.93% of its industry peers.
- CRL's Operating Margin has been stable in the last couple of years.
- CRL has a Gross Margin of 34.68%. This is in the lower half of the industry: CRL underperforms 61.40% of its industry peers.
- CRL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
- CRL has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for CRL has been increased compared to 5 years ago.
- The debt/assets ratio for CRL has been reduced compared to a year ago.
2.2 Solvency
- CRL has an Altman-Z score of 2.74. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 2.74, CRL is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
- The Debt to FCF ratio of CRL is 4.02, which is a neutral value as it means it would take CRL, 4.02 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of CRL (4.02) is better than 75.44% of its industry peers.
- A Debt/Equity ratio of 0.64 indicates that CRL is somewhat dependend on debt financing.
- CRL has a Debt to Equity ratio of 0.64. This is in the lower half of the industry: CRL underperforms 71.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Altman-Z | 2.74 |
ROIC/WACC0.54
WACC10.76%
2.3 Liquidity
- A Current Ratio of 1.37 indicates that CRL should not have too much problems paying its short term obligations.
- CRL has a worse Current ratio (1.37) than 78.95% of its industry peers.
- CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of CRL (1.10) is worse than 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
- CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.25%.
- The Earnings Per Share has been growing by 8.93% on average over the past years. This is quite good.
- Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -0.92% in the last year.
- The Revenue has been growing by 9.09% on average over the past years. This is quite good.
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
3.2 Future
- Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 6.56% on average per year.
- CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.25% yearly.
EPS Next Y0.17%
EPS Next 2Y3.1%
EPS Next 3Y5.39%
EPS Next 5Y6.56%
Revenue Next Year-0.56%
Revenue Next 2Y0.56%
Revenue Next 3Y1.89%
Revenue Next 5Y2.25%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- CRL is valuated rather expensively with a Price/Earnings ratio of 20.81.
- Compared to the rest of the industry, the Price/Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 91.23% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 26.94. CRL is valued slightly cheaper when compared to this.
- With a Price/Forward Earnings ratio of 20.01, CRL is valued on the expensive side.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 89.47% of the companies listed in the same industry.
- CRL is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.81 | ||
| Fwd PE | 20.01 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 92.98% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 89.47% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.87 | ||
| EV/EBITDA | 14.15 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)125.15
PEG (5Y)2.33
EPS Next 2Y3.1%
EPS Next 3Y5.39%
5. Dividend
5.1 Amount
- No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:CRL (1/21/2026, 9:35:03 AM)
219.52
+1.33 (+0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-17 2026-02-17/amc
Inst Owners107.25%
Inst Owner Change0.32%
Ins Owners0.89%
Ins Owner Change0.17%
Market Cap10.80B
Revenue(TTM)4.02B
Net Income(TTM)-83.48M
Analysts79.09
Price Target208.66 (-4.95%)
Short Float %5.28%
Short Ratio2.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.28%
Min EPS beat(2)2.88%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)10.51%
Min EPS beat(4)2.88%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.19%
EPS beat(12)12
Avg EPS beat(12)8.5%
EPS beat(16)16
Avg EPS beat(16)6.77%
Revenue beat(2)2
Avg Revenue beat(2)2.06%
Min Revenue beat(2)0.38%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.12%
Min Revenue beat(4)0.38%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.53%
Revenue beat(12)10
Avg Revenue beat(12)1.83%
Revenue beat(16)12
Avg Revenue beat(16)1.25%
PT rev (1m)7.99%
PT rev (3m)14.17%
EPS NQ rev (1m)0.2%
EPS NQ rev (3m)-1.83%
EPS NY rev (1m)0.01%
EPS NY rev (3m)0.44%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)0.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.81 | ||
| Fwd PE | 20.01 | ||
| P/S | 2.69 | ||
| P/FCF | 19.87 | ||
| P/OCF | 14.42 | ||
| P/B | 3.17 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.15 |
EPS(TTM)10.55
EY4.81%
EPS(NY)10.97
Fwd EY5%
FCF(TTM)11.05
FCFY5.03%
OCF(TTM)15.23
OCFY6.94%
SpS81.75
BVpS69.19
TBVpS-1.79
PEG (NY)125.15
PEG (5Y)2.33
Graham Number128.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| ROCE | 7.39% | ||
| ROIC | 5.84% | ||
| ROICexc | 6.03% | ||
| ROICexgc | 13.86% | ||
| OM | 11.73% | ||
| PM (TTM) | N/A | ||
| GM | 34.68% | ||
| FCFM | 13.51% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.64 | ||
| Debt/FCF | 4.02 | ||
| Debt/EBITDA | 2.43 | ||
| Cap/Depr | 48.19% | ||
| Cap/Sales | 5.12% | ||
| Interest Coverage | 4.36 | ||
| Cash Conversion | 83.34% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.74 |
F-Score4
WACC10.76%
ROIC/WACC0.54
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
EPS Next Y0.17%
EPS Next 2Y3.1%
EPS Next 3Y5.39%
EPS Next 5Y6.56%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
Revenue Next Year-0.56%
Revenue Next 2Y0.56%
Revenue Next 3Y1.89%
Revenue Next 5Y2.25%
EBIT growth 1Y-22.72%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year29.81%
EBIT Next 3Y11.7%
EBIT Next 5Y9.91%
FCF growth 1Y47.54%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y7.42%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?
ChartMill assigns a valuation rating of 5 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for CRL stock?
The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 0.17% in the next year.